Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.31 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28899530 | 0.94 | ESR1 (0.34) | ESR1 | |
| SCHEMBL2224883 | 0.86 | — | — | |
| SCHEMBL1021604 | 0.86 | GABRA1 (0.47) | KDM4EMAPTHPGDCYP3A4ALOX15 | |
| SCHEMBL194133 | 0.79 | KDM4E (0.40) | KDM4EMAPTHPGDCYP3A4ALOX15 | |
| SCHEMBL16308021 | 0.79 | KDM4E (0.40) | KDM4EMAPTHPGDCYP3A4ALOX15 | |
| SCHEMBL2028661 | 0.78 | HPGD (0.43) | SLC6A4KDM4EMAPTHPGDCYP3A4 | |
| SCHEMBL8752281 | 0.78 | MYC (0.36) | KDM4EMAPTHPGDCYP3A4ALOX15 | |
| SCHEMBL7091649 | 0.77 | — | — | |
| SCHEMBL7036350 | 0.76 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL7776205 | 0.74 | CA1 (0.46) | CYP3A4TP53TDP1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4138411-A | RUTHENIUM OR OSMIUM CATALYST | RHONE-POULENC S. A. (FR) | 1979-02-06 | — | — | US | claimed |
| US-12441669-B2 | PCNHCP metal complexes and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2025-10-14 | — | — | US | disclosed |
| US-20230322647-A1 | PCNHCP METAL COMPLEXES AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2023-10-12 | — | — | US | disclosed |
| WO-2022229784-A1 | MIXTURES OF EMULSIFIED TERPENES HAVING ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY | VILLAGOMEZ DIAZ, Jennifer Paulina (EC) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022043993-A1 | PCNHCP METAL COMPLEXES AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2022-03-03 | — | — | WO | disclosed |
| US-9572850-B2 | Use of cajeput and Pimenta racemosa extract for treating parasitic infestation of fish | MARS, INCORPORATED (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2461698-B1 | USE OF CAJEPUT AND PIMENTA RACEMOSA EXTRACT FOR TREATING PARASITIC INFESTATION OF FISH | MARS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120276227-A1 | USE OF CAJEPUT AND PIMENTA RACEMOSA EXTRACT FOR TREATING PARASITIC INFESTATION OF FISH | MARS, INCORPORATED (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2461698-A1 | USE OF CAJEPUT AND PIMENTA RACEMOSA EXTRACT FOR TREATING PARASITIC INFESTATION OF FISH | Mars, Incorporated (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-1363650-B1 | COMPOSITION CONTAINING PIMENTA EXTRACT IN AQUATIC ANIMAL TREATMENT METHODS | AQUARIUM PHARMA (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020164384-A1 | Aquatic animal treatment method and composition containing pimenta extract | AQUARIUM PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002069989-A2 | AQUATIC ANIMAL TREATMENT METHOD AND COMPOSITION CONTAINING PIMENTA EXTRACT | AQUARIUM PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | disclosed |
| US-20010036961-A1 | Substituted alkylene diamine compounds | CV THERAPEUTICS, INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001062711-A2 | SUBSTITUTED ALKYLENE DIAMINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-5173535-A | PLASTICS CONTAINING SUSTAINED RELEASE OF FUNCTIONAL MATERIALS | DOW CORNING CORPORATION (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0328145-A2 | Plastics containing discrete particles with functional materials | DOW CORNING CORPORATION (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4138411-A | RUTHENIUM OR OSMIUM CATALYST | RHONE-POULENC S. A. (FR) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | TNNC1, ATP2A1, ATP2A2 | ESR1 4835/4885SLC6A2 1864/4885SLC6A4 2866/4885 |
| US-20230322647-A1 | PCNHCP METAL COMPLEXES AND USES THEREOF | PIN4, HIRIP3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ESR1 1822/4885SLC6A2 1112/4885SLC6A4 1063/4885 |
| US-20010036961-A1 | Substituted alkylene diamine compounds | TNNC1, CPT1B, TNNI3 | ESR1 4752/4885SLC6A2 2150/4885SLC6A4 3568/4885 |
| US-12441669-B2 | PCNHCP metal complexes and uses thereof | PIN4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HIRIP3 | ESR1 2135/4885SLC6A2 922/4885SLC6A4 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.